You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Assessing Risk in Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: How to Approach Challenging Cases in the Clinic

  1. According to current expert opinion, when is the use of ctDNA recommended in patients with hormone receptor (HR)-positive, HER2-negative early breast cancer?
    At treatment initiation
    In patients with a high Ki-67
    Only in the setting of clinical trials